Atypical antipsychotics and the geriatric patient: Balancing safety and efficacy

Geriatrics

Volumn 62, Issue 7 SUPPL., 2007, Pages 3-18

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMIODARONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLARITHROMYCIN; CLOZAPINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; LOXAPINE SUCCINATE; MEMANTINE; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; QUETIAPINE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL; ZIPRASIDONE;

AGED; AGGRESSION; AGITATION; ATAXIA; BEHAVIOR THERAPY; BIPOLAR DISORDER; CAREGIVER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG INDICATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; HALLUCINATION; HUMAN; ILLUSION; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 34547587276     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965-1971.
2. Webster R, Holroyd S. Prevalence of psychotic symptoms in delirium. Psychosomatics. 2000;41:519-522.
3. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59:1721-1729.
4. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601-1608.
5. Centers for Medicare and Medicaid Services. Revised Long Term Care Resident Assessment Instrument (RAI) User's Manual for the Minimum Data Set (MDS) Version 2.0. Available at http://www.cms.hhs.gov/NursingHomeQualityInits/ 20_NHQIMDS20.asp#TopOfPage
6. Jeste D, Sable JA, Salzman C. Diagnosis of late-life disordered behavior, agitation, and psychosis. In: C S, ed. Clinical Geriatric Psychopharmacology (ed 4th edition). Baltimore, MD: Lippincott Williams & Wilkins; 2005:117-127.
7. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722-727.
8. Cohen-Mansfield Agitation Inventory. Available at: http://www.medafile. com/zyweb/CMAI.htm Accessed May 10, 2007
9. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29-34.
10. Trzepacz P, Breitbart W, Franklin J, et al. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry. 1999;156:1-20.
11. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157:172-178.
12. Porsteinsson AP RJ, Ismail MS, Tariot PN. Psychiatric Assessment and Treatment of Nonpsychotic Behavioral Disturbances in Dementia. In: PA Lichtenberg DM, AM Mellow., ed. Handbook of Dementia: Psychological, Neurological, and Psychiatric Perspectives. Vol. 12: John Wiley & Sons; 2003:335-357.
13. Armstrong SC, Cozza KL, Watanabe KS. The misdiagnosis of delirium. Psychosomatics. 1997;38:433-439.
14. Blazer DG, Steffens DC, Busse EW. The American Psychiatric Publishing textbook of geriatric psychiatry (ed 3rd). Washington, DC: American Psychiatric Pub.; 2004
15. Beier MT. Cholinesterase inhibitors and anticholinergic drugs: is the pharmacologic antagonism myth or reality? J Am Med Dir Assoc. 2005;6:413-414.
16. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113:941-948.
17. Stavitsky K, Brickman AM, Scarmeas N, et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2006;63:1450-1456.
18. Zhu CW, Scarmeas N, Torgan R, et al. Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology. 2006;66:1021-1028.
19. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:561-572.
20. Lawton MP, Van Haitsma K, Klapper J, Kleban MH, Katz IR, Corn J. A stimulation-retreat special care unit for elders with dementing illness. Int Psychogeriatr. 1998;10:379-395.
21. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-104.
22. Department of Health & Human Services (DHHS) CMMSC. The Nursing Home Surveyors State Operations Manual. Unnecessary Drugs. F-329. CMS Manual System (Pub 100-07 State Operations Provider Certification) 2006.
23. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.
24. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210-216.
25. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11:638-647.
26. Andreescu C, Mulsant BH, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007;68:194-200.
27. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329:75.
28. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14:767-776.
29. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
30. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry. 1997;154:1-39.
31. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538.
32. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47:716-719.
33. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003;53:1142-1145.
34. American Diabetes Association/American Psychiatric Association Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
35. Kryzhanovskaya LA, Jeste DV, Young CA, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients With Dementia. J Clin Psychiatry. 2006;67:933-945
36. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.
37. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-1115.
38. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
39. FDA US. FDA public health advisory: deaths wtih antipsychotics in elderly patients with behavioral disturbances.; April 11, 2005.
40. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
41. Jeste DV, Blazer D, Casey D, et al. Antipsychotic Drugs in Elderly Persons with Dementia: An Update. Neuropsychopharmacology. In press; 2007.
42. Flockhart DA. Drug interactions: cytochrome P450 system. http://medicine.iupui.edu/Flockhart Accessed June 8, 2007.
43. Abilify® Prescribing Information; 2006. NY: Bristol-Myers Squibb and Otsuka America Pharmaceuticals, Inc.
44. Geodon® Prescribing Information. 2007. NY: Pfizer.